Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB142 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part A [Single Ascending Dose (SAD)]: BIIB142 Cohort 1A | EXPERIMENTAL | Participants will receive Dose A of BIIB142 or a matching placebo on Day 1 in a fasted state. |
| Part A (SAD): BIIB142 Cohort 2A | EXPERIMENTAL | Participants will receive Dose B of BIIB142 or a matching placebo on Day 1 in a fasted state. |
| Part A (SAD): BIIB142 Cohort 3A | EXPERIMENTAL | Participants will receive Dose C of BIIB142 or a matching placebo on Day 1 in a fasted state. |
| Part A (SAD): BIIB142 Cohort 4A | EXPERIMENTAL | Participants will receive Dose D of BIIB142 or a matching placebo on Day 1 in a fasted state. |
| Part A (SAD): BIIB142 Cohort 5A | EXPERIMENTAL | Participants will receive Dose E of BIIB142 or a matching placebo on Day 1 in a fasted state. |
| Part A (SAD): BIIB142 Cohort 6A | EXPERIMENTAL | Participants will receive BIIB142 on Day 1 in the fasted followed by fed state in the first sequence, and vice versa in the second sequence. A washout period of 14 days will be maintained between both the sequences. Dose will be determined based on emerging PK data. |
| Part B [Multiple Ascending Dose (MAD)]: BIIB142 Cohort 1B | EXPERIMENTAL | Participants will receive Dose A of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state. |
| Part B (MAD): BIIB142 Cohort 2B | EXPERIMENTAL | Participants will receive Dose F of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state. |
| Part B (MAD): BIIB142 Cohort 3B | EXPERIMENTAL | Participants will receive Dose D of BIIB142 or a matching placebo administered orally once daily for 14 days in a fasted state. |
| Name | Type | Description |
|---|---|---|
| BIIB142 | DRUG | Administered Orally |
| BIIB142-Matching Placebo | DRUG | Administered Orally |
Key Inclusion Criteria: * Have a body mass index between 18 and 32 kilograms per square meter (kg/m\^2), inclusive, at screening. * Weight ≥ 50 kilograms (kg) at screening. * Negative polymerase chain reaction (PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Check-in p...
BIIB142 is an investigational small molecule drug being developed by Biogen Inc. (ticker BIIB). It is in Phase 1 clinical development, and its intended therapeutic indications have not been disclosed. The only registered study to date is a safety and pharmacokinetic trial in healthy adult volunteers.
BIIB142 targets IRAK4, a kinase. IRAK4 is the molecular target of this small molecule, which places BIIB142 in the kinase inhibitor class. Biogen is developing the compound, and it is currently in Phase 1 testing in healthy volunteers rather than in patients with a disclosed disease.
Biogen Inc., which trades under the ticker BIIB, is developing BIIB142. Biogen is the sponsor of the compound's registered Phase 1 study. No other developer or partner is associated with BIIB142 in its registered clinical program.
BIIB142 is in Phase 1 clinical development. It is investigational and has not been approved by the FDA for any use. The program currently consists of a single Phase 1 study that is recruiting healthy adult participants aged 18 to 55 years in the United States.
BIIB142 is being studied in one Phase 1 trial, NCT07133828, titled a study to learn about the safety of BIIB142 and how it is processed in the body of healthy adult participants aged 18 to 55 years old. The trial is recruiting 78 healthy volunteers in the United States and is randomized, double-blind, and controlled.